Sponsor Overview
Explore verified public information about Accendatech USA Inc.'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 1 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria Our EA policy will apply to those DMG patients who exhausted standard of care and can't find appropriate trials to participate. We encourage a patient's provider (pediatric neuro-oncologist) to reach out to us so that we can discuss the case with the provider before an EA decision can be made based on the clinical data we collected so far and the information from each patient. Available Therapies via Single-Patient EA ACT001 for DMG treatment
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.